Executive Summary Antibody drug conjugates (ADCs) have become one of the most important innovations in oncology and the broader biotech industry in recent years. Over the past decade, antibody drug conjugates have evolved from early-stage research tools into an integrated system spanning science, clinical development, manufacturing, and market strategy. Understanding ADCs solely from the perspective of molecular design or clinical efficacy is no longer sufficient. Antibody d